Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELENE 2: Phase 3 study of AZD6234 in adults with overweight or obesity and type 2 diabetes mellitus
CTR20263959Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of lenbelintide in obesity, Overweight, type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Aug 2026; status: active.
02
Drugs
lenbelintide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20263959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263959.